ClinicalTrials.gg
Not yet recruitingNCT07546396Updated Apr 22, 2026

Methadone Rapid Restart

A Phase 4 interventional study of Methadone in Opioid Use Disorder, sponsored by Pouya Azar. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Pouya Azar · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.

Planned enrollment
14th of 19
25 · median 68
Started
2026
the only one that year
Phase 4
5 of 19
2 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
Pouya Azar

Among the 19 studies testing methadone in Opioid-Related Disorders, this one is the 14th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 19th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing methadone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

The usual treatment for opioid use disorder (OUD) is opioid agonist therapy (OAT) with either methadone or buprenorphine. These treatments are well-established, reduce the risk of fatal overdoses, and are considered the standard approach. However, current methadone guidelines were developed when most people were using heroin, which is far less potent than today's unregulated/illicit fentanyl supply. As a result, people who use fentanyl often need higher doses to feel stable. Because methadone must be started at low doses and increased slowly, it can take weeks before someone reaches an effective dose. This process becomes even longer when doses are missed, since treatment often needs to be restarted at a lower level.

The Methadone Rapid Restart is a newer strategy designed to take ongoing fentanyl use into account. Early clinical experience and modelling suggest that many people who use fentanyl have high opioid tolerance and may be able to return to their previous stable methadone dose even after several missed days, without added safety risk. This approach has shown promise in small clinical settings, but it is not yet known whether it provides better outcomes than the standard methadone titration used today. This study will be testing whether this protocol to help rapidly restart people on Methadone is acceptable for patients and use the learning to guide a subsequent larger clinical trial.

Read the detailed description

Canada continues to see the ongoing effects of the illicit drug overdose in the last decade. Fentanyl and fentanyl analogues account for the majority illicit drug overdose deaths with the highest rate of opioid-related deaths in Canada occurring in British Columbia (BC). Despite this rapid rise in unregulated fentanyl use, treatment strategies for people who use unregulated fentanyl still rely on the opioid use disorder (OUD) treatment guidelines developed from research conducted in people using heroin, a relatively less potent opioid. Currently, methadone and buprenorphine are the recommended medications for opiate use disorder (MOUD).

Methadone at higher doses (at least 60-120mg/day) has shown to have greater effectiveness and treatment retention as compared to lower dosages, based on studies with patient populations using heroin (Bromley et al. 2021). It therefore stands to reason that in the age of unregulated fentanyl, even higher doses of methadone are likely necessary to achieve optimal efficacy and retention rates. Despite this, the highest recommended starting dose of methadone is currently 40mg with a maximum of 15 mg increase every 3 days, for those with a known very high tolerance. As a result, it takes several weeks for people using unregulated fentanyl to reach an effective dose, which is further compounded by missed doses. It is also recommended that if 4 doses of methadone are missed, patients restart at at 50% of their previous dose or at 30-40mg, whichever is higher; and if 5 or more consecutive doses are missed, patients receive a full re-titration, starting from 30-40mg. However, emerging clinical and pharmacokinetic data suggest that, as long as opioid tolerance remains unchanged, methadone can be safely restarted at the same stable dose after missing 4-8 subsequent doses.

The proposed study aims to determine the safety and efficacy of continuing maintenance dose methadone after 4-8 missed doses in people continuing to use unregulated fentanyl to meet their opioid needs.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Opioid Use Disorder
  • Opiate Agonist Therapy
  • Methadone
  • Medications for Opiate Use Disorder
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19 years or older
  2. Opioid use disorder (OUD) of any severity by TR Clinical Diagnostic criteria [American Psychiatric Association, 2022]
  3. Previously 'stable' on methadone as per the below definitions:

    1. Previous maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period.
    2. Participants who were being titrated on methadone for opioid use disorder prior to discontinuation. If participants were on the most recent dose for less than 5 days, they can be restarted on the prior dose providing they cumulatively received 5 consecutive doses (with a maximum of 1 missed dose in that period) between the two most recent dosages.
  4. Missed 4-8 doses of methadone in a row leading up to intake assessment.
  5. Participant able to provide baseline opiate use history as per opiate use screening questions in Appendix A. This must provide an estimate of opiate use prior to stopping methadone and change in use since stopping.
  6. Self-reported increased use of fentanyl since stopping methadone.
  7. No significant change in opiate withdrawal symptoms as compared to when on methadone, based on self-report and examination.
  8. Urine drug test (UDT) positive for fentanyl at screening or within 24 hours prior to re-initiating methadone.
  9. Participant wishes to continue methadone maintenance treatment.
  10. If applicable the participant must be willing to complete a urine pregnancy test to ensure they are not currently pregnant.
  11. Participants will require a baseline that demonstrates a \< 500ms.
  12. For participants from VGH study site specifically:

    1. must be admitted to either psychiatry or CTU, ideally with planned admission of at least 3 days.
    2. must agree if discharged prior to the completion of the 7 day follow up period, to either return to VGH Diamond Centre for follow up assessments on Days 1/3/7 (+/-2 days).
    3. must have access to a functioning cell phone to allow for the study team to contact them in case of discharge prior to completion of study follow up period.
  13. The participants must be willing and able to provide written for study participation.

Exclusion criteria

Exclusion Criteria:

  1. COWS score of 8 or more at the time of clinician assessment
  2. Self-reported Opioid overdose or naloxone administration since methadone discontinuation or during the 5 days prior to methadone discontinuation
  3. Self-reported New cardiac disease diagnosis since methadone discontinuation
  4. Self-reported Intolerable side effects reported when taking methadone
  5. Individuals who are pregnant (urine pregnancy test) or breast-feeding (self-reported)
  6. Use of buprenorphine-naloxone (Suboxone®, Sublocade®, Butrans ®) within the previous 3 days (self-reported)
  7. Participants with a >500 msec on the screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Methadone rapid restart for participants on methadone maintenance treatment

    Participants who have missed 4-8 doses of methadone, but were on maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period. These participants will be re-initiated on 100% of their most recent methadone dose.

    Drug: Methadone

  • Experimental
    Methadone rapid restart for participants being titrated on methadone

    Participants who have missed 4-8 doses of methadone, but were being titrated on methadone prior to discontinuation such that they were on their most recent dosage for less than 5 days but received at least 5 consecutive days of methadone between the prior two dosages (with a maximum of 1 missed dose in that period) be. These participants will be restarted on the lower of their two most recent dosages.

    Drug: Methadone

Interventions

  • Participants who meet study inclusion criteria and have no exclusion criteria, who have missed 4-8 doses of methadone will, be administered methadone according to the stratification below and will continue the same dose for the 7 day follow up. * Arm 1: Previous maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period. These participants will be re-initiated on 100% of their most recent methadone dose. * Arm 2: Participant was being titrated on methadone prior to discontinuation such that they were on their most recent dosage for less than 5 days but received at least 5 consecutive days of methadone between the prior two dosages (with a maximum of 1 missed dose in that period) be. These participants will be restarted on the lower of their two most recent dosages.

    Also known as: Metadol-D, Methadose

06

What researchers measure

Primary outcomes

  1. Enrollment rate

    Number of participants enrolled per month

    Time frame: Enrollment

  2. Patient Satisfaction

    At the end of the follow up period participants will be asked, "Overall, how satisfied were you with the methadone restart protocol?" The response will be recorded on a 7-point scale: 1=extremely dissatisfied; 2= very dissatisfied; 3= somewhat dissatisfied; 4=neither satisfied nor dissatisfied; 5=somewhat satisfied; 6=very satisfied; 7=extremely satisfied.

    Time frame: Assessed retrospectively at the end of 7 day follow up period.

Secondary outcomes

  1. Recruitment

    Number of patients approached, eligible, and enrolled

    Time frame: Through study completion, anticipated to be 12 months

  2. Level of sedation

    Pasero Opioid-Induced Sedation Scale (Score range: 1-4) : Minimal/No sedation (score: 1-2), High sedation (score: 3-4)

    Time frame: Baseline, Intervention (1, 2, and 3 hour post-dose) and follow up (Day 1, 3 and 7)

  3. Blood Pressure

    Systolic and diastolic blood pressure

    Time frame: Baseline, intervention (1,2, and 3 hour post methadone dose), and follow up (Day 1, 3, and 7)

  4. Oxygen saturation

    Oxygen saturation

    Time frame: Baseline, intervention (1, 2, and, 3 hour post dose) and follow up (Day 1, 3, and 7)

  5. Respiratory rate

    Respiration rate

    Time frame: Baseline, intervention (1, 2 and 3 hour after post methadone dose), and follow up (Day 1, 3, and 7)

  6. Heart rate

    Heart rate

    Time frame: Baseline, intervention (1, 2 and 3 hour after post methadone dose), and follow up (Day 1, 3, and 7)

  7. Change in unregulated substance use patterns

    The change in the unregulated substance use patterns assessed at baseline and end of the methadone restart protocol

    Time frame: Baseline and follow up (Day 1, 3, and 7)

  8. ECG

    QTc levels in Electrocardiogram

    Time frame: Baseline and follow up (Day 3 and 7)

  9. Adverse events

    Incidence of adverse events (AEs) possibly/probably/definitely related to the study drug

    Time frame: During intervention and follow up

  10. OAT retention

    Retention of methadone and other opioid agonist therapy

    Time frame: Follow up

  11. Overdose and hospitalization

    Rate of overdose and hospitalization

    Time frame: Follow up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2027, 10 months later.

Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 10 months is below that.

Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 22, 2026
StartEst.
May 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07546396
Lead sponsor
Pouya Azar
Responsible party
Pouya Azar (Principal Investigator, University of British Columbia) — Sponsor-investigator
First posted
Apr 22, 2026
Start date
May 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

James Wong
Contact
james.wong@vch.ca
(604) 875-5823
Pouya Azar
principal investigator · Department of Psychiatry, Faculty of Medicine, University of British Columbia and Vancouver General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion